Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

Mukesh Kumar, Aruna K. Behera, Richard F. Lockey, Jian Zhang, Guraman Bhullar, Cristina Perez de la Cruz, Li Chen Chen, Kam W. Leong, Shau Ku Huang, Shyam S. Mohapatra

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 μg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-γ production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.

Original languageEnglish
Pages (from-to)1415-1425
Number of pages11
JournalHuman Gene Therapy
Volume13
Issue number12
DOIs
Publication statusPublished - Aug 10 2002
Externally publishedYes

Fingerprint

Nanospheres
Respiratory Syncytial Virus Infections
Chitosan
Respiratory Syncytial Viruses
DNA
Genes
Lung
Bronchiolitis
Methacholine Chloride
Viral Antigens
Antibodies
Cytotoxic T-Lymphocytes
Viral Load
Nose
Immunoglobulin A
Interferons
Pneumonia
Plasmids
Asthma
Immunoglobulin G

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Kumar, M., Behera, A. K., Lockey, R. F., Zhang, J., Bhullar, G., Perez de la Cruz, C., ... Mohapatra, S. S. (2002). Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Human Gene Therapy, 13(12), 1415-1425. https://doi.org/10.1089/10430340260185058

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. / Kumar, Mukesh; Behera, Aruna K.; Lockey, Richard F.; Zhang, Jian; Bhullar, Guraman; Perez de la Cruz, Cristina; Chen, Li Chen; Leong, Kam W.; Huang, Shau Ku; Mohapatra, Shyam S.

In: Human Gene Therapy, Vol. 13, No. 12, 10.08.2002, p. 1415-1425.

Research output: Contribution to journalArticle

Kumar, M, Behera, AK, Lockey, RF, Zhang, J, Bhullar, G, Perez de la Cruz, C, Chen, LC, Leong, KW, Huang, SK & Mohapatra, SS 2002, 'Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection', Human Gene Therapy, vol. 13, no. 12, pp. 1415-1425. https://doi.org/10.1089/10430340260185058
Kumar, Mukesh ; Behera, Aruna K. ; Lockey, Richard F. ; Zhang, Jian ; Bhullar, Guraman ; Perez de la Cruz, Cristina ; Chen, Li Chen ; Leong, Kam W. ; Huang, Shau Ku ; Mohapatra, Shyam S. / Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. In: Human Gene Therapy. 2002 ; Vol. 13, No. 12. pp. 1415-1425.
@article{0629bd4c5ff74086a742f61784520483,
title = "Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection",
abstract = "Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 μg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-γ production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.",
author = "Mukesh Kumar and Behera, {Aruna K.} and Lockey, {Richard F.} and Jian Zhang and Guraman Bhullar and {Perez de la Cruz}, Cristina and Chen, {Li Chen} and Leong, {Kam W.} and Huang, {Shau Ku} and Mohapatra, {Shyam S.}",
year = "2002",
month = "8",
day = "10",
doi = "10.1089/10430340260185058",
language = "English",
volume = "13",
pages = "1415--1425",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

AU - Kumar, Mukesh

AU - Behera, Aruna K.

AU - Lockey, Richard F.

AU - Zhang, Jian

AU - Bhullar, Guraman

AU - Perez de la Cruz, Cristina

AU - Chen, Li Chen

AU - Leong, Kam W.

AU - Huang, Shau Ku

AU - Mohapatra, Shyam S.

PY - 2002/8/10

Y1 - 2002/8/10

N2 - Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 μg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-γ production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.

AB - Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 μg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-γ production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.

UR - http://www.scopus.com/inward/record.url?scp=0036382826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036382826&partnerID=8YFLogxK

U2 - 10.1089/10430340260185058

DO - 10.1089/10430340260185058

M3 - Article

C2 - 12215263

AN - SCOPUS:0036382826

VL - 13

SP - 1415

EP - 1425

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -